Genentech taps small Boston pharma in $20M respiratory, eye drug research deal
Pieris Pharmaceuticals Inc., a small biotech behind a suite of inhalable, engineered proteins it calls anticalins, saw its stock surge more than 100% after signing a major research-and-development pact with Genentech Inc. for respiratory and ophthalmology treatments.
South San Francisco-based Genentech — the North American biotech unit of Swiss drug giant Roche — is paying Pieris (NASDAQ: PIRS) $20 million up front, with the potential for another $1.4 billion in milestone payments, plus royalties.…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Rowan Walrath Source Type: news
More News: American Health | Biotechnology | Health Management | Opthalmology | Pharmaceuticals | Respiratory Medicine | Switzerland Health | USA Health